---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-271933"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:43:05.213832+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MAIA reports Q3 net loss $4.9M; THIO shows 100% DCR in second-line NSCLC, FDA IND cleared

## Summary
- Cash $6.1M at Sep 30, 2023 vs $10.9M at Dec 31, 2022; net loss $4.9M ($0.36/share) unchanged YoY.
- THIO-101 Phase 2 trial achieved 100% disease control rate in second-line NSCLC, exceeding standard of care 53-64%.
- FDA cleared THIO IND for U.S. enrollment in THIO-101; 49 patients dosed, enrollment pace exceeding similar trials.
- First two subjects on trial reported long-term survival of 14.6 and 12.5 months with no new anti-cancer treatment.
- R&D expenses $2.6M (up from $2.3M); G&A $2.4M (up from $1.7M) due to professional fees and investor relations.

## SEC filing metadata
- accession: 0001193125-23-271933
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000119312523271933/0001193125-23-271933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000119312523271933/d578280d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-271933
- JSON: https://secwatch.observer/filing/0001193125-23-271933.json
- Plain text: https://secwatch.observer/filing/0001193125-23-271933.txt

## Key facts
- Earnings Releases
  MAIA Biotechnology, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was approximately $4.9 million, or $0.36 per share, for the quarter ended September 30, 2023, EPS $0.36 per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net loss was approximately $4.9 million, or $0.36 per share, for the quarter ended September 30, 2023
  - EPS: $0.36 per share
  - Result: reported results
  source text: MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312523271933/0001193125-23-271933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.